VERAXA Biotech (NASDAQ: VRXA) is expanding its use of human-relevant testing methods across its oncology research programs, a strategic shift that could improve the predictive value of preclinical data and reduce reliance on animal testing in cancer drug development. The Switzerland-based biotechnology company, with a key financial and regulatory presence in the U.S., outlined in an October 7, 2026, announcement its implementation of New Approach Methodologies (NAMs), a collection of non-animal research techniques that includes cell-based assays, computational modeling and three-dimensional spheroid models. The move matters because traditional animal studies often fail to predict human responses, contributing to high attrition rates in oncology clinical trials. By adopting FDA-aligned NAMs, VERAXA aims to generate more clinically informative data earlier, potentially accelerating the development of its BiTAC T-cell engagers, BiTAC-based antibody-drug conjugates and bispecific antibody-drug conjugates for cancer treatment.
According to the company, new three-dimensional spheroid data reinforce the ability of its models to assess the dual-target specificity of its lead T-cell engager candidates. In an ex vivo study involving 10 low-passage patient-derived xenograft models of non-small cell lung cancer, only about 10 mice were required, compared with an estimated 200 or more for comparable in vivo efficacy studies. The company says its lead BiTAC candidate induced potent T-cell-mediated tumor-cell killing across the tested models, while relevant controls showed minimal activity. This dramatic reduction in animal use, coupled with the preservation of human-relevant tumor biology, underscores the efficiency gains the strategy could deliver.
The implications extend beyond animal welfare. For investors, the adoption of NAMs signals a commitment to more robust, human-relevant preclinical packages that regulators increasingly favor. The FDA has been encouraging such approaches through programs like the Modernization Act 2.0, which allows alternatives to animal testing in certain contexts. For VERAXA, the strategy could shorten timelines and lower costs associated with preclinical development, while also strengthening the scientific rationale for its antibody-based pipeline. As the company advances its BiTAC candidates toward the clinic, the ability to demonstrate dual-target specificity and potent tumor killing in human-relevant models may enhance the credibility of its data with partners and regulators.
The announcement also positions VERAXA within a broader industry trend toward human-relevant testing, where biotechnology companies are seeking to bridge the translational gap between bench and bedside. With its focus on T-cell engagers and antibody-drug conjugates, VERAXA is targeting some of the most promising modalities in immuno-oncology, and the integration of NAMs could provide a competitive edge in a crowded field. The company’s lead BiTAC candidate’s performance across patient-derived models, along with the minimal activity of controls, offers early evidence that its human-relevant approach is yielding meaningful results.
As VERAXA continues to implement NAMs across its preclinical programs, the coming months will reveal whether this strategy translates into faster progress toward clinical trials and, ultimately, differentiated cancer therapies. The company’s newsroom, available at https://ibn.fm/VRXA, provides ongoing updates on its pipeline and testing methodologies. For a deeper look at VERAXA’s expansion of human-relevant testing, the full announcement can be accessed through Read More. The original release is also available on www.newmediawire.com.
